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Recent technological advances have enabled investigators to characterize the moleculargenetics and genomicsofhepatic neoplasia
in remarkable detail. From these studies, an increasing number of molecular markers are being identiﬁed that correlate with
clinically important tumor phenotypes. This paper discusses current knowledge relevant to the molecular classiﬁcation of
epithelial primaryhepatic tumorsthatariseinadults,includingfocalnodularhyperplasia (FNH), hepatocellular adenoma(HCA),
hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC. Genetic analysis has deﬁned molecular
subtypes ofHCAthatareclinicopathologicallydistinctandcanbe distinguishedthroughimmunohistochemistry.Geneexpression
studieshaveidentiﬁedmolecularsignaturesofprogressionfromdysplasticnodules(DNs)toearlyHCCincirrhosis.Analysesofthe
mutational spectra, chromosomal aberrations and instability, transcriptomics, and microRNA proﬁles of HCC have revealed the
existence ofbiologicallydistinctsubtypes ofthiscommonmalignancy,withprognosticimplications.Molecularcharacterizationof
biliaryandhepaticprogenitorcell phenotypesinlivercancerhasshednewlightonthehistogenesisofthesetumorsandhasfocused
attention on novel therapeutic targets. In coming years, the molecular classiﬁcation of hepatic neoplasms will be increasingly
valuable for guiding patient care, as targeted therapies for liver cancer are developed and brought into clinical practice.
1.Introduction
Over the past decade, tremendous advances have been
made in the technologies available for characterizing the
molecular genetics, genomics and epigenetics of neoplasia.
These advances have greatly accelerated basic research aimed
atelucidatingthemolecularmechanisms underlyingtumori-
genesis. In addition, they have led to the identiﬁcation of
molecular markers that correlate with important biological
characteristics of tumors. Such markers are increasingly
valuable in clinical practice as tools for facilitating the
diagnosis and categorization of tumors, determining their
aggressiveness and, in some cases, predicting their responses
to particular forms of therapy. The ideal classiﬁcation system
for any group of neoplasms would be based on our under-
standing of their ontogeny and would integrate histologic
features with molecular data in a clinically meaningful way.
In this paper, we will discuss the molecular biology of pri-
mary hepatic tumors, with particular emphasis on the roles
of molecular characterization in clinical practice. We will
focus on primary hepatic neoplasms that arise in adults,
including hepatocellular adenoma (HCA), hepatocellular
carcinoma (HCC), cholangiocarcinoma (CC), and the rare
entity, combined hepatocellular and cholangiocarcinoma
(HCC-CC). Focal nodular hyperplasia (FNH), although
thought to be a nonneoplastic lesion, is often considered
in the diﬀerential diagnosis of other hepatocytic tumors
and, therefore, has also been included in this discussion.
However, consideration of mesenchymal, hematopoietic and
childhood liver tumors is beyond the scope of this review.
FNH is the most common of the benign hepatocellular
tumors, arising in approximately 3% of adults [1, 2].
Although the other major type of benign hepatocellular
tumor, HCA occurs much less frequently, with an esti-
mated incidence in Europe and North America of 0.003%
[3], its association with hemorrhage, rupture, and risk of
malignant transformation necessitates itsaccuratediagnostic
distinction from FNH. This is an area in which molecular2 Pathology Research International
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Figure 1: Schematic illustration of the histologic spectrum of benign hepatocellular proliferations. Polyclonal FNH is at one end of the
spectrum and nontelangiectatic HCA is at the other; inﬂammatory HCA (I-HCA), formerly classiﬁed as telangiectatic FNH (T-FNH), has
overlapping features and is shown in the middle. Gray areas indicate ﬁbrosis; green and red dots represent bile ductules and arterioles,
respectively.
characterization has become very informative and clinically
useful. The most common primary hepatic malignancy is
HCC, which constitutes 80–85% of all malignant epithelial
neoplasms originating in the liver. HCC often arises in
a background of cirrhosis and presents a global public
health problem far greater than that of HCA. In the United
States, the annual incidence of HCC has been rising over
the past three decades [4]. The second most common
primary hepatic malignancy is CC, constituting 15–20%
of the total, and its incidence has also been rising. There
has been an explosion of basic research in the ﬁeld of
primary hepatic epithelial cancers in recent years, and we are
just beginning to understand their molecular pathogenesis.
We anticipate rapid advancements over the next several
years in personalized medical approaches to the treatment
of liver cancer, as the molecular mechanisms of hepatic
tumorigenesis are elucidated and molecular classiﬁcation of
these lesions is integrated into clinical study design [5].
2.Focal NodularHyperplasia
Focal nodular hyperplasia (FNH) is a common, benign
hepatocellular lesion that is believed to arise in response to
localized hyperperfusion of the liver parenchyma, typically
in association with a microscopic arterial malformation [6,
7]. FNH frequently presents as an incidental hepatic mass
noted in imaging studies, and it can often be diagnosed
on the basis of its radiographic appearance alone. However,
sometimes the diagnosis requires histologic conﬁrmation.
Althoughthegrossmorphologyandmicroscopicappearance
of FNH in resection specimens are usually characteristic and
easily recognized, distinguishing FNH from HCA in needle
biopsies can be diﬃcult. The distinction is, however, of great
importance because of the diﬀering clinical management of
these entities.
Traditionally, FNH has been considered nonneoplastic
and, accordingly, it is thought to have no malignant poten-
tial. However, molecular analyses of the clonality of FNH
have yielded conﬂicting results, with some studies ﬁnding
that up to 50% show X chromosome inactivation patterns
suggestive of monoclonality [7, 8]. In general, polyclonality
argues strongly against neoplasia, but the implications of
monoclonality are less clear, since it may be inﬂuenced by
factors such as variability in X-inactivation patterns, tissue
architectureandturnoverrate.Thus,thequestionofwhether
classic FNH is sometimes neoplastic remains controversial.
AtypicalformsofFNHhavebeendescribed,includingmixed
lesions with both FNH-like and HCA-like areas, as well as
lesions with histologic features intermediate between FNH
and HCA [9]. The latter tumors were originally designated
“telangiectatic FNH” (T-FNH), but subsequent molecular
analyses have led to their reclassiﬁcation as a variant of HCA
(see below). Mixed FNH-HCA have not been subjected to
molecular analysis and, indeed, have not been described in
recent publications. Therefore, their existence as a distinct
entity is uncertain. Although FNH and variants of HCA
comprise a histologic spectrum (Figure 1), there is no
compelling evidence that they are biologically related in the
sense of one being the precursor of another.
Given the uncertainty surrounding the issue of neoplasia
in FNH, several investigators have searched for genetic
alterations that might deﬁne these lesions. If a genetic
abnormality characteristic of FNH were found, it would
greatlysupportitsneoplasticnature,andtheﬁndingcouldbe
diagnostically useful in clinical practice. However, the results
of such studies thus far have been uniformly negative, with
no mutations detected in the APC, axin, β-catenin, HNF1α,
or p53 genes in classic FNH [8, 10–12].
Both FNH and HCA consist predominantly of well-
diﬀerentiated hepatocytes. In FNH, there are intervening
ﬁbrous bands that radiate from a central scar and contain
abundant, proliferating bile ductules. In contrast, HCA have
only rare bile ductules, if any, and typically show much
less ﬁbrosis. However, the regions of ﬁbrous scar in FNH
are variable in abundance and are not always adequately
sampled inneedle biopsies, sometimes making the histologic
distinction from HCA diﬃc u l t .W eh a v ef o u n dt h a tt h e
expression patterns of biliary markers, as determined by
immunohistochemistry, are frequently diﬀerent in FNH and
HCA, not only within regions containing bile ductules,
but also in hepatocellular areas [13]. Antibodies against
cytokeratin 19 (CK19) and neuronal cell adhesion molecule
(NCAM,also known as CD56),which are markers of hepatic
progenitor cells as well as biliary epithelium, clearly stain
the proliferating ductules within ﬁbrous tracts in FNH
and rare, isolated ductules in HCA. Cytokeratin 7 (CK7),
which is known to be a marker of immature hepatocytesPathology Research International 3
as well as progenitor cells and biliary epithelium [14],
shows a distinct pattern of expression in HCA [15]t h a t
distinguishesthelatterfromFNHinmostcases(Figure 2).In
our experience, although occasional needle biopsies remain
diagnostically challenging even after the combined use of
immunohistochemicalstainsforCK7andCK19,thisanalysis
is usually quite helpful in the diﬀerential diagnosis of FNH
and HCA [13, 16].
Immunohistochemical staining for the cytoplasmic
enzyme, glutamine synthetase (GS), has also been proposed
asatechniquefordiﬀerentiatingbetweenFNHandHCA[2].
GS is an enzyme that combines glutamate with ammonia
to produce the amino acid glutamine. In normal liver,
GS expression is limited to the centrilobular hepatocytes
that directly border central veins, and its most important
function is to aid in ammonia detoxiﬁcation [17]. In recent
years, the Wnt signaling pathway has been identiﬁed as
a critical regulator of zonation in the liver [18]. Beta-
catenin activation in perivenular hepatocytes, presumably
the result of Wnt signaling from central veins, drives the
expression of GS. In FNH, the centrilobular zones of β-
catenin activation are expanded [12], and this leads to
an irregular, geographic distribution of GS overexpression
[2]. In HCA and HCC, several diﬀerent patterns of GS
expression have been observed, all distinct from that seen
in FNH. As discussed later, activating mutations of the β-
catenin gene occur in a subset of HCA. In adenomas with
β-catenin mutation, GS is diﬀusely expressed, whereas in
adenomas with normal β-catenin, GS is absent in large areas
of the lesion. Unfortunately, however, in the latter type of
HCA, irregular and/or centrizonal expression of GS can be
present focally, particularly at the periphery of the tumor
[2]. Therefore, although GS expression appears to robustly
diﬀerentiateFNHfrom HCAin full resection specimens, it is
less reliable for making this distinction in needle biopsies.
3.HepatocellularAdenoma(HCA)
First described a half-century ago, HCAisa rare, benignliver
tumor that most commonly occurs in women and has been
associated with oral contraceptive use [19]. It is a neoplasm
of demonstrated clonal origin [20, 21]a n dh a sas m a l l
but nonnegligible risk of malignant transformation [22].
Hemorrhage, pain, and rupture are other, more frequent
complications of HCA, and their likelihood is proportional
to the size of the tumor [1]. Histologically, HCA is a
proliferation of mature-appearing hepatocytes arranged in
cordsone to two cells thickand lacking portal tracts. Isolated
arterioles surrounded by hepatocytes and lacking a ﬁbrous
sheath (“naked”or “unpaired” arteries) can beseen scattered
throughout the lesion. Arterioles accompanied by portal
venules may be observed in a few portal-like structures, but
these lack bile ducts. In some HCA, occasional isolated bile
ductulesmaybeseen,especially whenimmunohistochemical
stains for CK7 or CK19 are applied.
In 2002, Bluteau et al. published the results of a genome-
wide search for tumor suppressor genes in HCA [23].
Microsatellite analysis revealed a loss of heterozygosity
(a)
(b) (c)
Figure 2: Patterns of immunohistochemical positivity for CK7 in
benign hepatocellular lesions.(a)FNH displaysstrongCK7staining
of proliferating ductules but virtually no positivity within hepa-
tocytes. (b) An example of HCA (nonmutated, noninﬂammatory
type) showing focal, moderate CK7 staining within hepatocytes
as well as heavy staining of a few bile ductules. (c) An I-HCA
containing areas of bile ductular proliferation (arrow) with strong
CK7 expression, resembling a ductular reaction in FNH, as well
as other areas (e.g., bottom of image) in which there is focal
hepatocellular staining for CK7, as is typical of HCA.
(LOH) for markers at chromosome 12q caused by a small
deletion of this region in ﬁve out of ten HCA. The TCF1
gene, encoding hepatocyte nuclear factor 1 (HNF1), was
found to reside within the deletion. Because the function of
HNF1 as a liver-speciﬁc transcription factor was already well
established, this gene was pursued as the most likely candi-
date tumor suppressor aﬀected by LOH in these adenomas.
Further investigation conﬁrmed that in ten out of sixteen
HCA analyzed, HNF1 was somatically inactivated, either
through a combination of gene deletion and mutation or via
bi-allelic mutation. Interestingly, germline mutation of the
HNF1genehad beenpreviously discoveredtounderlie a rare
form of familial noninsulin dependent diabetes, MODY3
(maturity-onset diabetes of the young, type 3) [24]. This
form of diabetes is associated with an increased risk of hep-
aticadenomatosis,duetorandomsomaticinactivation ofthe
second, nongermline-mutant HNF1 allele in the liver [25].
Shortly after genetic alterations of HNF1 in HCA were
reported, a group in Taiwan published their discovery of
activating mutations of the β-catenin gene in a fraction of
these tumors. Earlier work by many independent groups had
implicated Wnt pathway activation in liver carcinogenesis,
and β-catenin mutations have been found in a signiﬁcant
percentage of HCC. To investigate the possibility that
aberrant β-catenin signaling plays a role in very early hepatic4 Pathology Research International
neoplasia, Chen et al. performed directed LOH analysis and
genomic sequencing of several Wnt pathway genes [10].
Three of ten HCA were found to bear small, in-frame
deletions in one allele of the β-catenin gene, and to express
truncated forms of the protein that are predicted to be
constitutively activated.
The French group that had originally identiﬁed HNF1
inactivation in HCA next expanded their study to include
assessment of β-catenin mutation status as well as genotype-
phenotype correlations in these tumors [26]. In a collection
of 96 HCA, 44 were found to have HNF1 gene inactivation
and to display a characteristic histology, including marked
hepatocellular steatosis, a lack of cytologic atypia, and an
absence of inﬂammatory inﬁltrates in the lesion. Beta-
catenin mutation was identiﬁed in 12 of the 96 tumors and
was frequently associated with histologic features suggestive
of malignancy, including nuclear atypia and pseudoacinar
formation. Importantly, β-catenin mutation and HNF1
inactivation were mutually exclusive in these tumors, indi-
cating the existence of at least two distinct, nonoverlapping
molecular subtypes of HCA.
In the 1990s, a class of histologically unusual hepatic
tumors was described and termed “telangiectatic FNH”
(T-FNH) [9]. These lesions lacked a central scar, but
because they displayed focal ductular reaction and a nodular
architecture, they were categorized as an atypical variant of
FNH. However, the sinusoidal dilatation, naked arterioles,
and frequent intralesional hemorrhage that typiﬁed T-FNH
were recognized as being similar to HCA (Figure 1). These
peculiar features of T-FNH invited molecular characteriza-
tion and comparison with both classic FNH and HCA. Two
groups performed clonality assays and found a much higher
rateofmonoclonalityinT-FNHthaninclassicFNH[11,20].
The angiopoietin mRNAexpression pattern, which had been
shown to diﬀer between FNH and HCA, was found in T-
FNHtoresemblethatofHCA,andaglobalproteomicproﬁle
of T-FNH matched that of HCA while distinguishing both
T-FNH and HCA from classic FNH [20]. Together, these
ﬁndings strongly suggest that so-called telangiectatic FNH is
actually a variant of HCA.
In the genotype-phenotype study described above, HCA
that were found not to harbor genetic alterations in either
HNF1 or β-catenin were further subdivided into two groups
o nt h eb a s i so ft h ep r e s e n c eo ra b s e n c eo fi n ﬂ a m m a t o r y
inﬁltrates. The subgroup showing inﬂammation, named
inﬂammatory HCA (I-HCA), was found to include all
lesions formerly classiﬁed as T-FNH. Thus, four subtypes of
HCA were proposed: (1) HNF1-inactivated HCA (H-HCA),
(2) β-catenin-mutated HCA (β-HCA), (3) I-HCA, and (4)
nonmutated, noninﬂammatory HCA [26]. A subsequent
study of 93 HCA (47 of which had been previously analyzed)
supported this classiﬁcation system in general, except that β-
catenin mutation was discovered to occur in a fraction of I-
HCA as well as in noninﬂammatory HCA [27].
The hypothesis that I-HCA represents a biologically
distinct entity was greatly strengthened with the ﬁnding
of a marked overexpression of acute-phase reactants by
the hepatocytes of these lesions [27]. At both the mRNA
and the protein level, serum amyloid A (SAA) and C-
reactive protein (CRP) are signiﬁcantly overexpressed in
I-HCA relative to nonneoplastic liver. When all types of
hepatocellular adenoma are examined, the sensitivity and
speciﬁcity of SAA overexpression by immunohistochemistry
for identifying I-HCA was found to be 94%. The degree of
SAA overexpression did not correlate with the extent of inﬁl-
tration by inﬂammatory cells, which suggested that acute-
phase protein expression might be an intrinsic feature of the
neoplastic hepatocytes, whereas inﬂammatory inﬁltration
might be secondary. To explore this possibility, Rebouissou
et al. undertook a genome-wide mRNA expression study,
comparing I-HCA to normal liver, and identiﬁed a pro-
nounced activation of acute-phase inﬂammatory signaling
in I-HCA [28]. Further inquiry into the potential causes
of this inﬂammatory gene expression signature led to the
discovery of mutations in the IL6ST gene, which encodes
gp130, a component of the IL-6 receptor, in 60% of I-HCA
[28]. These IL6ST mutations lead to ligand-independent
activation of the IL-6 receptor, which promotes STAT3 sig-
naling and induces the acute-phase inﬂammatory response
within hepatocytes. The recruitment of inﬂammatory cells
into I-HCA appears to be secondary to gp130-mediated
hepatocellular production of the chemokine, CCL20, which
attracts immune cells. In this study, all 43 I-HCA were found
to show expression signatures indicative of IL-6 pathway
activation, even those tumors in which no IL6ST mutation
was identiﬁed. In I-HCA lacking IL6ST mutation, no other
geneticalterations couldbeidentiﬁedinvarious components
of the STAT3 signaling pathway. However, gp130 protein
levels were elevated in most of these lesions, suggesting that
posttranslational controlofgp130was aberrant, perhaps due
to occult mutation of a gene that normally regulates gp130’s
protein abundance.
In summary, HCA can be assigned to one of four
categories [3]. The ﬁrst is H-HCA and is deﬁned by HNF1
inactivation. This variety accounts for 35–40% of all HCA
and occurs almost exclusively in women. Rarely, these
tumors arise in the context of familial diabetes (MODY3)
and can be multiple. H-HCA can be identiﬁed through
immunohistochemical staining for liver fatty acid binding
protein (LFABP), which is a transcriptional target of HNF1
and is completely absent in the hepatocytes of these lesions.
Histologically, H-HCA usually displays marked steatosis but
no inﬂammation, and it lacks cytologic atypia. The second
category, I-HCA, comprises over 50% of all HCA. It is
characterized by the presence of inﬂammatory inﬁltrates,
focal ductular reaction, sinusoidal dilation, and dystrophic
arterioles. I-HCA almost invariably shows dramatic over-
expression of acute-phase reactants, including SAA and
CRP, which can be demonstrated by immunohistochemistry
(Figure 3). Although the HNF1 gene is never inactivated in
I-HCA, β-catenin mutations are sometimes found [29]. This
type of HCAis associated with obesity, smoking, and alcohol
consumption and is the most common variety of HCA in
men.
The third category of HCA is somewhat controversial
and consists of lesions that harbor activating mutations of
β-catenin but are noninﬂammatory; it has been reportedPathology Research International 5
that approximately 10% of adenomas belong to this β-HCA
subtype. Beta-catenin activation is most easily assessed
through immunostaining for glutamine synthetase, which
is diﬀusely overexpressed in these lesions. Alternatively,
immunohistochemical staining for β-catenin itself may be
used to distinguish between tumors without mutation, in
which β-catenin has a membranous localization, and those
with mutation, in which an aberrant, activated form of β-
catenin accumulates within nuclei. In both I-HCA and β-
HCA, β-catenin mutation has been associated with a high
risk of malignancy. These tumors are common in men,
and they often show features, such as pseudoacini and
hepatocellular dysplasia, that are frequent in HCC. In fact,
because β-HCA may be histologically indistinguishable from
well-diﬀerentiated HCC [28], theirexistence as a biologically
distinct entity has been called into question. A group in the
United States has recently reported their failure to ﬁnd any
examples of β-HCA in a collectionof 41 adenomas subjected
to molecular analysis [30]. We feel that in well-diﬀerentiated
hepatocellular tumors, the presence of β-catenin mutation
in association with morphologic features suspicious for
malignancy should warrant a pathologic diagnosis of either
outright or suspected hepatocellular carcinoma, rather than
HCA.This isan area inneed offurther research todetermine
the molecular diﬀerences, if any exist, between β-HCA and
HCC.Suchﬁndings wouldhelptoelucidatethepathogenesis
of HCC and might serve as the basis for a diagnostic test of
malignancy in histologically equivocal cases.
The fourth and ﬁnal category of HCA are those that are
noninﬂammatory (negative for acute phase markers) and do
not harbor mutations in HNF1, β-catenin, or gp130. This
is the smallest group of HCA, accounting for only about
5% of the total. Lesions that cannot be fully evaluated due
to extensive necrosis and/or hemorrhage are also classiﬁed
in this group. Whether these noninﬂammatory, nonmutant
tumorsrepresentatrulydistinctsubtypeofHCA,orwhether
they are biologically related to one or more of the other
three subtypes, is an open questionthat awaits further inves-
tigation.
4.HepatocellularCarcinoma(HCC)
HCC almost always arises in the context of chronic liver
disease, usually in patients with cirrhosis. Cirrhosis of any
etiology constitutes the predominant risk factor for HCC.
Worldwide, infection with hepatitis B virus (HBV) accounts
for the majority of cases, whereas in the United States,
chronic hepatitis C is the most common predisposing factor.
HCC is often diagnosed late in the course of disease, but
in developed countries, surveillance programs that use im-
proved radiologic techniques for monitoring liver lesions in
patients with cirrhosis are leading to increased rates of early
HCC detection.
4.1. Dysplastic Nodules and Early Hepatocellular Carcinoma
in Cirrhosis. It is now well accepted that in cirrhotic livers,
the vast majority of HCC arise from benign precursor
lesions called dysplastic nodules (DN) [31]. Although fully
Figure 3: Immunohistochemical staining for serum amyloid A
(SAA) in an inﬂammatory HCA shows strong, diﬀuse positivity in
the tumor (right) but virtually no staining in adjacent normal liver
(left).
developed HCCs typically show histologic features that
are easily recognizable to pathologists, the morphologic
distinction between advanced DN and early HCCs is often
more subtle and can be very diﬃcult to identify, especially
in needle biopsies [32]. As the molecular genetic events that
drive the early steps of hepatic carcinogenesis are more fully
elucidated, it is anticipated that molecular markers will be
found that can help pathologists in making these clinically
important distinctions. Indeed, in recent years, molecular
analyses of the dysplasia-to-carcinoma pathway in cirrhosis
have begun to yield valuable information for the recognition
and classiﬁcation of early hepatic neoplasia.
Several groups have used gene expression proﬁling to
identify “molecular signatures” that can accurately distin-
guish betweenDNand early HCC[33–37].Perhaps themost
promising of these studies is that of Llovet et al., which
analyzedtheexpressionpatternsof55hepatocarcinogenesis-
related genes in dysplastic nodules and early HCCs of
hepatitis C-infected patients. These authors identiﬁed a
panel of only three genes (GPC3, LYVE1 and survivin)
whose mRNA expression levels, as assessed by quantitative
reverse transcription-PCR (qRT-PCR), were shown to cor-
rectly predict malignancy in 19 out of 20 early HCCs and
nonmalignancy in 16 out of 17 DNs. As a test for HCC in
this sample set, the sensitivity ofthis 3-gene expression panel
was 95% and its speciﬁcity was 94%. Two of the genes in
the panel, GPC3 (which encodes glypican-3) and survivin,
are expressed by hepatocytes and are upregulated in HCCs,
as compared to DN. The third gene, LYVE1, is expressed
by endothelial cells and is downregulated in malignancy.
All three genes had been previously implicated in hepatic
carcinogenesis, andtheirdiﬀerentialexpressionlevelsinDNs
and HCCsismost likelyindependentoftheunderlying cause
ofcirrhosis. The advantage of using qRT-PCR toidentify this
sort ofmolecularsignatureisthatthemethod ishighlyquan-
titative, much more so than conventional immunohisto-
chemistry, and, therefore, more objective. However, a disad-
vantage is that it must be performed on pure lesional tissue,6 Pathology Research International
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Figure 4: Glutamine synthase expression is (a) restricted to perivenular (zone 3) hepatocytes in normal liver but (b) diﬀuse and strong in
HCC.
which can be scarce in needle biopsies. Furthermore, the
method requires the sacriﬁce of a small amount of lesional
tissue for RNA extraction and thus necessitates the destruc-
tion of some potentially valuable histologic information.
Nevertheless,in cases withan adequateamount of tissue,this
qRT-PCR-based approach has the potential for considerable
practical utility. If its predictive accuracy can be shown to
extend to lesions that arise in cirrhosis of all etiologies, and if
it can be successfully employed for the analysis of formalin-
ﬁxed needle biopsies, it may become a valuable adjunct to
histology for diﬀerentiating between DN and early HCCs.
The gold standard for diagnosis of DN and early
HCCs is still histology; in fact, internationally agreed upon
histologic deﬁnitions of these lesions and a standardized
nomenclature have only recently been formulated [32].
This morphologic classiﬁcation system was developed and
reﬁned on the basis of meticulous histologic analyses of
entire lesions within surgical resection specimens. It is
recognized that needle biopsiesof such lesions will often lack
areas that are critical for making a histologic diagnosis of
malignancy. In particular, the diagnosis of early HCCs may
require identifying the invasion of lesional hepatocytes into
portal tracts within the surrounding, benign parenchyma.
Because biopsies frequently fail to sample such areas, molec-
ular markers capable of distinguishing between dysplastic
and malignant hepatocytes are urgently needed. However,
because histology is still the gold standard for diagnosis, the
immunohistochemical assessment of molecular markers, as
an adjunct to standard H&E histology, is generally preferred
over nucleic acid analysis in clinical practice.
Many immunohistochemical markers have been assessed
individually,butwhathasemergedasmostusefulcurrentlyis
a panel of three markers: GPC3, GS, and HSP-70. Glypican-
3 was ﬁrst identiﬁed as a gene whose mRNA is frequently
expressed in HCC but not in benign, adult liver, HCA or
CC [38]. Numerous laboratories have since conﬁrmed the
overexpression of GPC3 in HCC at the mRNA and protein
levels. Its utility as an immunohistochemical marker for
HCC was ﬁrst demonstrated by Yamauchi et al., who found
diﬀusely positive GPC3 staining of malignant hepatocytes in
84% of HCCs and only focal, weak staining in a small set of
DN [39]. Similar results were obtained by Llovet et al. in the
study cited above.
In an eﬀort to augment the sensitivity of GPC3 im-
munostaining as a molecular test for HCC, and to retain
its speciﬁcity in distinguishing DN from malignant lesions,
Di Tommaso et al. examined the value of adding other
tumor markers to the analysis [40]. Heat-shock protein 70
(HSP70) is an antiapoptotic, “stress response” gene that
had been found through mRNA expression proﬁling to
be markedly upregulated in early HCC, as compared with
adjacent benign liver tissue [36]. Glutamine synthetase (GS)
is a metabolic enzyme (now known to be upregulated by β-
catenin signaling [41], as discussed above) that had also been
shown to be overexpressed in primary liver cancer (Figure 4)
[42]. When these three tumor markers, GPC3, HSP70, and
GS, were applied as an immunohistochemical panel to a set
ofbenignandmalignantnodulesthathadbeenresectedfrom
cirrhotic livers, positivity for any two of the three markers
was found to indicate malignancy with 72% sensitivity
and 100% speciﬁcity. In a recent study, these authors used
the same panel of immunostains to retrospectively analyze
needle biopsies of a similar set of lesions and found that
fordistinguishing between high gradedysplastic nodulesand
well- or very well-diﬀerentiated HCC, the sensitivity of two-
marker positivity as an indicator of malignancy decreased
from 72% to 49%, while its speciﬁcity remained 100% [43].
This reduction in sensitivity may be attributable to sampling
error and the somewhat heterogeneous expression patterns
of HSP70 and GPC3 proteins within HCC. It would bePathology Research International 7
interesting to know whether the mRNA expression patterns
of GPC3, LYVE1, and survivin suﬀer from the same sort
of intratumoral heterogeneity, which might complicate their
use as molecular markers for HCC in needle biopsies.
Although immunohistochemical staining for the GPC3/
HSP70/GS panel is currently recommended as the best ancil-
larytechniquetoaidinthediagnosisofearlyHCCindiﬃcult
needle biopsy specimens [44], the search continues for
biomarkers that can increase the sensitivity of this panel and
that are easily and reproducibly stainable in tissue sections.
Most candidate markers have been discovered through gene
expression studies, and beyond their practical diagnostic
utility, investigation into their functions in human liver and
in model systems has yielded important insights into the
mechanisms of hepatic carcinogenesis. A recent example of
gene expression proﬁling leading to this kind of basic insight
isprovidedby Kaposi-Novaket al.in theirstudy ofdysplastic
nodules and early HCC in cirrhotic liver explants [37]. In
additiontoidentifying molecularsignatures abletodiscrimi-
natebetweenregenerative,dysplastic, andmalignant nodules
as well as conﬁrming the upregulation of HSP70, GPC3, and
several other putative tumor markers in early HCC, these
investigators performed a comparative functional analysis of
DNandHCCsgeneexpressionsignatures. Their resultsshow
that the gene expression proﬁle of early HCCs diﬀers from
thatofDNsinapatternstronglysuggestiveofMYConcogene
activation. Interestingly, no mutations in the MYC gene were
detected by sequencing of HCC genomic DNA, and MYC
itself was not found to be overexpressed. However, a protein
called CSN5 (also known as Jab1) that had been previously
shown to posttranscriptionally promote MYC activation in
breast epithelium [45] was found to be overexpressed in
early HCC in parallel with induction of the MYC-regulated
geneexpression signature. This suggests amechanistic model
of early hepatocarcinogenesis in which an increase in the
expression of CSN5 within DN leads to aberrant MYC
activation,and therebydrivestheprogression ofthese lesions
to HCC. If this model proves true, it may have profound
implications for the molecular classiﬁcation, diagnosis, and
treatment of early HCC.
4.2. Hepatocellular Carcinoma Arising in Noncirrhotic Liver.
The overall incidence of HCCs in patients without cirrhosis
is diﬃcult to estimate and varies with geography and
t h ep r e v a l e n c eo fr i s kf a c t o r si nt h ep o p u l a t i o n[ 46, 47].
Most cases occur in association with chronic liver disease,
sometimes in a backgroundof hepatic ﬁbrosis that falls short
of full-blown cirrhosis. Consequently, the risk factors for
HCC development are the same in the absence of cirrhosis
as in its presence; they include chronic HBV or HCV
infection, chronic alcohol- or toxin-induced liver injury, and
nonalcoholic steatohepatitis [46, 48]. Noncirrhotic patients
with HCC are more likely than those with cirrhosis to have
multiple risk factors. Although the molecular pathogenesis
of hepatic malignancy is likely variable, with some genetic
alterations more common in lesions that arise in association
with particular risk factors than others, there is no strict
correlation between the etiology of underlying chronic liver
disease and histologic or molecular subtype of HCCs (see
below).
Hepatocellular carcinomas that arise in the absence of
chronic liver disease or known risk factors for malignancy
are almost always a histologic variant known as ﬁbrolamellar
HCC(FL-HCC).The greatmajority of thesetumorsoccurin
patients under the age of 35, and they display a characteristic
histology, with nests of large, oncocytic, malignant hepato-
cytessurroundedbythickbandsoflayeredﬁbrosis. Although
the rarity of these tumors has hampered eﬀorts to elucidate
their molecular pathogenesis, FL-HCCs have been found to
contain unique molecular alterations that distinguish them
from the more common forms of HCCs (reviewed in [49]).
The diagnosis of FL-HCCs depends mostly on histology,
with the application of immunohistochemical markers when
needed [50], and the recognition of clinical characteristics
typical of this distinct clinicopathologic entity.
4.3. Hepatocellular Carcinoma Heterogeneity. Hepatocellular
carcinoma has long been known to display extraordinary
genetic complexity and molecular heterogeneity. However,
it is not clear which of the many genomic, genetic, and
epigenetic alterations found in HCCs are the most critical in
driving its molecular evolutionand/or deﬁning its biological
behavior. For this reason, there is currently no molecular
subclassiﬁcation of HCCs that is widely accepted and rou-
tinely implemented in clinical practice. Nonetheless, a host
of molecular genetic markers have been found to correlate
with clinical parameters, and in some instances, to have
independent prognostic value in particular circumstances.
Althoughinrecentyears,surveillanceofthoseathighrisk
of hepatic malignancy has initiated a trend toward earlier
diagnosis of liver cancer, a substantial majority of HCC
patients still present with locally advanced or metastatic
disease [51]. Even among those whose cancer is diagnosed
at a stage early enough to allow them to undergo potentially
curativetherapy(suchasresection,percutaneousablation,or
liver transplantation), the rate of tumor recurrence remains
signiﬁcant. Overalllong-termsurvival ofpatientswith HCCs
is poor, in part because most suﬀer from concomitant,
underlyingchronicliverdisease.However,ratesofrecurrence
and metastasis are not uniform, even within stage-matched
patient groups, and there is evidence that from their
beginnings, HCC tumors show individual variability in their
degreeofintrinsic biologicalaggressiveness[52].Inaddition,
the number of therapeutic options for HCCs is growing
rapidly, due to advances in ﬁelds such as interventional
radiology and transplantation as well as the emergence of a
large armamentarium of molecularly targeted antineoplastic
drugs [53, 54]. Thus, for HCC patients at all stages, there is
a need for prognostic and predictive biomarkers that can aid
in the subclassiﬁcation of these tumors and help to identify
patients who are most likely to respond to each available
treatment modality.
4.4. Chromosomal Abnormalities and Genetic Mutations in
HCC. HCCs generally show a high level of chromosomal
instability, and this is a phenotype that is acquired early8 Pathology Research International
in the process of carcinogenesis [55]. Thus, chromosomal
a b e r r a t i o n sa r ec o m m o ni nt h i st y p eo fc a n c e r .H o w e v e r ,
there is an enormous variety of alterations that can occur,
and they have been found throughout the genome. Many of
these chromosomal alterations are undoubtedly “passenger”
changes, rather than the “drivers” of tumor progression. In
the past decade, advances in genomics technologies such
as the development of array-based comparative genomic
hybridization (array CGH) have allowed investigators to
map HCC-associated chromosomal alterations at a much
higher resolution than was previously possible. A number
of chromosomal regions have now been identiﬁed in which
gains or losses occur frequently in HCCs (reviewed in [56]),
and progress is being made in determining which genes
are the targets of these recurrent changes. For example,
by comparing array CGH data with global gene expression
patterns (determined using DNA microarrays) in 49 HCC
samples,Patiletal.wereabletocorrelatetherecurrentgainin
chromosome 8q with Jab1 overexpression [57]. Interestingly,
this is the same gene (also known as CSN5) whose overex-
pression was recently implicated in the activation of MYC
that appears to drive the progression of DN to early HCC
[37].Thus,8qgainmaybeacommonmechanismpromoting
early hepatocarcinogenesis.
Although high-resolution mapping of chromosomal
alterations in cancer is valuable mostly as a research tool,
a group in Japan has demonstrated that HCCs can be
subclassiﬁedintodistinct,clinicallymeaningful groupsbased
solely on their patterns of chromosomal alterations [58].
In this study, hierarchical cluster analysis was performed
on the genomic gain/loss proﬁles of 87 HCCs, and the
tumors were found to partition into two classes, termed A
and B. Chromosomal alterations were more numerous in
cluster A and typically included gains of 1q, 6p, and 8q
as well as 8p losses; this group of tumors was associated
with poor patient survival. Cluster A was further subdivided
into three subgroups, each characterized by speciﬁc high-
level ampliﬁcations (1q and 6p, 8q, and 17q). Cluster B
contained two important subgroups, one without frequent
chromosomal alterations and another with ampliﬁcation of
17q. The authors reasoned that by analogy with known
gene ampliﬁcations in other cancer types, the recurrent
ampliﬁcations they discovered in HCC subgroups might
indicate the presence of important oncogenes and that these
oncogenesmightbesuitabletherapeutictargets.Accordingly,
the vascular endothelial growth factor A gene (VEGFA)
was found to be contained within the ampliﬁed region of
chromosome 6p in a subgroup of cluster A tumors, and a
gene encoding an eﬀector molecule of the mTOR signaling
pathway was found to reside within the ampliﬁed region
of 17q. The frequent high-level copy number gain of the
6p region encompassing VEGFA has been conﬁrmed in
a larger set of HCC tumors and correlated with VEGFA
overexpression [59]. Both VEGF and the mTOR pathway are
promising therapeutic targets in liver cancer. Therefore, the
predictive value of ampliﬁcations at 6p and 17q in HCCs
as molecular markers of response to VEGF- and mTOR-
targeted therapies should be further explored in clinical
studies.
The quantitative assessment of genomic alterations as an
indicator of tumor aggressiveness has proven useful in pre-
dictingtheriskofHCCrecurrenceafterlivertransplantation.
In an eﬀort to identify molecular markers of recurrence risk
in HCC patients who had undergone transplantation, Marsh
et al. analyzed explanted tumors for loss of heterozygosity
(LOH) of microsatellite markers at nine tumor suppressor
gene loci [60]. They found that the amount of allelic loss
demonstrated within a particular tumor, when combined
with other parameters such as tumor size and patientgender,
correlated signiﬁcantly with risk of tumor recurrence. In a
subsequent study, the panel of microsatellite markers used
in this analysis was reﬁned, and a simple measure of the
amount of LOH detected in each tumor was developed,
called the fractional allelic imbalance (FAI) [61]. The
measurement of FAI and determination of the presence or
absence of macrovascular tumor invasion form the basis
of the Pittsburgh staging system [62], which is reported to
more accurately predict the risk of HCC recurrence after
transplantation thanstaging systemsbasedon radiologicand
clinical parameters [63].
HCCs have been extensively analyzed for the detection
of somatic mutations aﬀecting known oncogenes and tumor
suppressors (reviewed in [64]). The gene encoding β-catenin
(CTNNB1),whichismutatedinapproximately30%ofHCC,
is the oncogene most frequently activated in this cancer.
HCC bearing β-catenin mutations are more likely than
theirnonmutantcounterpartstoshowchromosomestability,
an absence of HBV infection [65], a well-diﬀerentiated
histology,andcholestasis[66].However,thereare conﬂicting
data in the literature on the question of whether β-catenin
mutationin HCC is associated with favorable or unfavorable
prognosis [67, 68]. In general, tumor suppressor genes are
more often mutated in HCC than oncogenes. The tumor
suppressor most commonly mutated in HCC, overall, is
TP53 (encoding the well-known cell cycle regulator, p53),
but its frequency of mutation varies with geographical
location. TP53 mutation in HCC occurs most commonly
in Asia and Africa, where the combination of widespread
dietary aﬂatoxin exposure and endemic hepatitis B fosters a
high rate of mutagenesis in the liver [69]. In the West, TP53
mutations are considerably less frequent, aﬀecting about
20% of HCCs. TP53 mutation in these tumors is associated
with poor prognosis, chromosomal instability, and HBV
infection [64].
4.5. Gene Expression Proﬁling and Molecular Subtypes of
HCCs. A large number ofstudieshave examined global gene
expression patternsin HCCsusing DNAmicroarray technol-
ogy (reviewed in [70, 71]). The advantage of this approach is
that it provides information about which signaling pathways
and cellular processes are activated or suppressed in these
tumors, regardless of the mechanisms (e.g., mutational
or epigenetic) underlying the aberrant regulation. Indeed,
transcriptomic analysis has led to the identiﬁcation of repro-
ducible HCC subtypes with diﬀering cellular diﬀerentiation
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andmaysoon allowbetterpatientstratiﬁcation fortreatment
than current clinical HCC staging systems.
In 2004, a group led by Dr. Thorgeirsson at the National
Cancer Institute published the results of a genome-wide
expression study of 91 HCCs showing that the tumors fell
into two subclasses with distinct mRNA expression proﬁles
and dramatically diﬀerent patient survival [72]. The poor
survival group, designated A, displayed gene expression
signatures of high cellular proliferation and low apoptotic
rate. A subsequent study, in which human HCC expression
proﬁles were compared with those of rodent hepatocytes
(fetal hepatoblasts, adult hepatocytes, and genetically engi-
neered murine HCC), led to further subdivision of group A
HCCsintohepatoblast-like(HB)andmaturehepatocyte-like
(HC) subgroups [73]. The hepatoblast gene signature was
associatedwithearlierrecurrenceandworsesurvivalthanthe
hepatocyte signature, and this association was independent
ofotherpathologicvariables.Theauthorsspeculatedthatthe
HB phenotype may reﬂect the origin of this subset of tumors
from adult hepatic progenitor cells (HPCs), which, like
fetal hepatoblasts, are able to diﬀerentiate into both cholan-
giocytes and hepatocytes. Consistent with this hypothesis,
several well-known HPC markers such as cytokeratins 7 and
19 (CK7 and CK19) were found to be included in the HB
gene signature.
The existence of two broad categories of HCCs, one with
and the otherwithout a “high-proliferation” gene expression
signature, has been conﬁrmed in multiple, independent
studies [71]. Most have found that tumors of the high-
proliferation group are more aggressive and less histolog-
ically diﬀerentiated than the group lacking this expression
signature. Boyault et al. presented a remarkably detailed
reﬁnement of this molecular classiﬁcation system, in which
three subgroups of each major category of HCC were
identiﬁed (yielding a total of six HCC subtypes) through
expression analysis followed by correlation with various
genetic, genomic, and clinical factors [74]. Although not yet
clinicallyapplicable,thissortofanalysishelpstoelucidatethe
biological basis of HCC heterogeneity and provides a foun-
dation for future prospective studies aimed at correlating
treatment responses with molecular subtype classiﬁcation.
The epithelial cell adhesion molecule, EpCAM, is a
known marker of fetal hepatoblasts and adult hepatic pro-
genitor cells as well as biliary epithelium. In 2004, Kim et al.
performed microarray studies of cirrhotic liver and found
that EpCAM is dramatically overexpressed in premalignant
l e s i o n sa sw e l la si nas u b s e to fH C C[ 75]. Molecular
characterization of the EpCAM-expressing HCC subgroup
demonstrated a signature of coexpressed genes that included
other HPC markers, such as c-kit and CK19 [76]. The
further stratiﬁcation of tumors into four groups according
to EpCAM expression and the patients’ α-fetoprotein (AFP)
status (positive or negative for elevated serum AFP) was
shown to deﬁne four prognostic categories, each with a
characteristic gene expression pattern. Importantly, this
result was replicated in three independent cohorts of HCC
(all HBV-related), in one of which the EpCAM analysis was
performed by immunohistochemistry, rather than mRNA
hybridization. Thus, the EpCAM-AFP classiﬁcation system
has the potential for easy application in clinical practice. It is
not yet clear whether the stratiﬁcation of AFP-positive cases
according to EpCAM expression will be clinically useful as
a prognostic indicator, since AFP positivity is already well-
known to be associated with aggressiveness in HCC [77].
However,thereisevidencethatEpCAMexpressioncorrelates
with biological variables that can be targeted therapeutically,
and, therefore, it may prove valuable as a predictive marker
of responsiveness to antiangiogenic therapies [78], Wnt/β-
catenin pathway inhibitors, and/or stem-cell targeted agents
such as anti-EpCAM antibodies [79].
Gene expression proﬁling has yielded novel insights into
the biological heterogeneity of HCCs and has particularly
highlighted the importance of hepatic progenitor cell/stem-
cell characteristics in deﬁning its aggressiveness. In addition,
these studies have focused attention on the roles of “cancer
stem-cells” in HCCs [79]. However, much remains to be
learned about the origins and behavior of hepatic progenitor
cell lineages in benign and premalignant conditions, as well
as their relationships to cancer stem-cells, cell-population
dynamics within tumors, and the clinicopathologic rami-
ﬁcations of stem-cell marker expression in diﬀerent HCC
molecular subtypes (Figure 5). Although it is not yet clear
which gene signatures and molecular markers will have the
broadest applicability, recent rapid progress in this ﬁeld
implies that the incorporation of molecular data into HCC
classiﬁcation and staging systems in the near future will lead
to continued improvements in the clinical management of
HCC.
4.6. MicroRNA Proﬁling of HCCs. MicroRNAs (miRNAs)
are short, noncoding RNA molecules that regulate gene
expression by binding to speciﬁc messenger RNAs and pre-
venting their translation into protein. Because each type
of miRNA is able to downregulate hundreds of genes at a
time, miRNAs often control entire transcriptional programs
thatdeterminefundamentalcellularpropertiesandbehavior.
Accordingly, miRNA proﬁling has emerged as an extremely
valuable method for phenotyping and subclassifying tumors
[80]. Compared to conventional gene expression proﬁling
(in which protein-coding, messenger RNAs are examined),
miRNA analysis has several advantages. Due to the stability
of miRNAs, formalin-ﬁxed samples (rather than frozen tis-
sue)canbeused.Furthermore,theinterrogationofhundreds
of miRNAs (and often signiﬁcantly fewer) yields as much
information as might be gleaned from examining thousands
of messenger RNAs.
Many independent groups have conducted compre-
hensive analyses of miRNAs in HCC, and a plethora of
informative miRNA markers have been identiﬁed. Many of
these miRNA signatures correlate with important biological
parameters, such as metastasis [81–83], diﬀerentiation [83–
85], HBV or HCV infection [86, 87], tumor recurrence
[88], and patient survival [89–91]. In addition to providing
new candidates for investigation as possible diagnostic,
prognostic, and/or predictive molecular markers in HCCs,
these studies are opening new avenues in basic research
on the mechanisms of hepatocarcinogenesis. For example,10 Pathology Research International
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Figure 5: Hypothetical classiﬁcation of primary hepatic malignancies according to corresponding patterns of hepatic progenitor cell
diﬀerentiation. Dashed lines illustrate possible lineages of tumor origin and evolution. At left is well-diﬀerentiated HCC, with a mature
hepatocytic phenotype (orange), and at right is cholangiocarcinoma, showing complete biliary diﬀerentiation (green). Varying degrees
and patterns of expression of progenitor cell markers (purple) and biliary-type cytokeratins (CK7, CK19) correlate with increased tumor
aggressiveness.
Ji et al. [92] have discovered that miRNA-181 is overex-
pressed in EpCAM-positive HCC cells and is a critical, func-
tionaldeterminantoftheprogenitorphenotypeinthesecells.
MiRNA-181 appears to promote a HPC phenotype by down
regulating the expression of key transcription factors that
mediate the diﬀerentiation and maturation of hepatocytes.
It has been shown recently that the reduced expression
(silencing) of miRNA-26 in HCC tumors of male pa-
tients is associated both with poor survival and response
to interferon-alpha adjuvant therapy [89]. Interestingly,
miRNA-26 is diﬀerentially expressed according to gender
in benign liver, with signiﬁcantly higher expression in
women than in men. Among individuals with HCC, those
whose benign liver tissue showed low miRNA-26 expression
were found to have tumors in which miRNA-26 was even
further downregulated, whereas in patients whose benign
liver miRNA-26 expression levels were high, tumor levels of
this miRNA were unchanged. These ﬁndings suggested that
miRNA-26 acts as a tumor suppressor in the liver and that
its higher expression in females may be a protective factor
against HCC and may contribute to the marked gender bias
in risk for this malignancy. Intriguingly, an analysis of gene
expression in tumors that had undergone miRNA-26 silenc-
ing revealed the activation of interleukin-6 (IL-6) signaling
networks. This is interesting in light of recent evidence that
estrogen-related inhibition of IL-6 signaling underlies the
observed female-speciﬁc resistance to hepatocarcinogenesis
in mice [93]. An even more exciting ﬁnding with regard to
miRNA-26 in human HCC was that miRNA-26 silencing
within tumors identiﬁed the subgroup of patients who ben-
eﬁted from postoperative treatment with interferon-alpha
after HCC resection in randomized trials [89]. The idea that
the tumors most likely to respond to interferon treatment
are those in which miRNA-26 silencing has led to increased
proinﬂammatory and IL-6 signaling is intuitively appealing.
Future prospective studies will undoubtedly test the eﬃcacy
of interferon-alpha in preventing recurrence of miRNA-26-
silenced HCC in broader patient populations, as well as its
valuein combinationwith othertherapeuticregimens. Thus,
miRNA-26promises tobecomethe ﬁrst predictive molecular
markerin HCCthatcan beused tomatch individual patients
with the treatments most likely to beneﬁt them.
5.IntrahepaticCholangiocarcinomaand
Combined HCC-CC
Cholangiocarcinoma (CC), deﬁned as carcinoma of biliary-
type epithelium, can arise in the liver parenchyma or any-
where along the extrahepatic biliary tract. The extrahepatic
type (which includes“Klatskin tumors” of the liver hilum) is
much more frequent, accounting for up to 90% of CC cases
[94]. The histologic appearance of intrahepatic CC (ICC)
is the same as that of extrahepatic forms, typically showing
malignant glands embedded in a prominent desmoplastic
stroma. Although these morphologic features usually make
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be conﬁrmed through staining for the hepatocytic marker,
HepPar-1, and the biliary markers, CK7 and CK19), it can
be diﬃcult to diﬀerentiate between ICC and metastasis to
the liver from a nonhepatic primary tumor. A few new
molecular markers of biliary diﬀerentiation have recently
been described [95], but these have not yet been tested for
their ability to distinguish ICC from hepatic metastasis.
CC generally presents at a late stage, when curative resec-
tion is no longer possible. Unfortunately, this malignancy is
highly aggressive and resistant tostandard chemotherapeutic
regimens. Molecular characterization of CC is in the early
investigative stages (reviewed in [96]), and useful prognostic
molecular markers have not yet been reported. The need
for more research in this area, and for the development of
targeted therapies and predictive molecular markers, is well
recognized.
Combined HCC-CC is a rare primary liver tumor
characterized by the intimate intermingling of histologically
unequivocal HCC and CC components [97]. Most cases
show, in addition to typical HCC and CC areas, transitional
regions containing immature-appearing cells that express
hepatic progenitor markers such as EpCAM. When such
transitional regions predominate, the tumor is classiﬁed as
a subtype of HCC-CC, “with stem-cell features” [98]. Three
histologic patterns of intermediate/stem-cell distribution
have been described in lesions of this category, including a
pattern sometimes termed cholangiolocarcinoma, formerly
classiﬁed as a variant of CC. Although several immunohisto-
chemical studies of HCC-CC have conﬁrmed the expression
of various hepatic progenitor cell markers in these lesions
[99, 100], their classiﬁcation is based on histomorphology,
rather than positivity for stem-cell markers perse.T h e
fact that many HPC markers are also expressed by biliary
epithelium and the recent ﬁndings on progenitor cell marker
expression by HCC greatly complicate this ﬁeld. Thus,
although there is evidence that HCC-CC arises from a
bipotential hepatic progenitor cell, the histogenesis of this
rare neoplasm is still debated (Figure 5).
Only a few studies have examined the molecular charac-
teristics of HCC-CC. Zucman-Rossi’s group in France used
microsatellite-based LOH analysis to assess chromosome
stability in 9 CC, 15 HCC-CC, and 3 HCC/CC collision
tumors [101]. Combined HCC-CC was found to show a
high degree of chromosomal instability, similar to CC and
unlike HCC. Investigators in Germany recently reported
the results of CGH analysis of 49 HCC, 22 hepatic CC,
and 7 HCC-CC cases [102]. In this study, combined HCC-
CC was found to resemble both HCC and CC, showing
several of the speciﬁc chromosomal gains and losses typical
of HCC, while also displaying a high total number of
chromosomal imbalances, similar to CC. Woo et al. recently
performed gene expression proﬁling of 70 HCC, 13 CC, and
7 HCC-CC [103]. Results showed that the gene expression
pattern of HCC was markedly diﬀerent from that of CC,
and combined HCC-CC clearly clustered with CC. Further
analysis led to the identiﬁcation of a CC gene signature
containing many known biliary and hepatic progenitor
cell markers. Interestingly, closer examination of the HCC
data revealed that a subset of HCC also expressed the CC
gene signature; this subset was designated CC-like HCC
(CLHCC). Expression of the CC gene signature by HCCs
was associated with poor prognosis. However, its prognostic
signiﬁcance was found to be independent of previously
described poor-prognostic gene signatures such as that of
the hepatoblast subtype of HCC. Thus, there are many layers
of complexity regarding hepatic progenitor cell and biliary
phenotypes in primary liver cancers. Overall, stem-cell
and biliary characteristics seem to correlate with increased
tumor aggressiveness, resistance to chemotherapy, and poor
prognosis.
6.Conclusions
In recent years, remarkable progress has been made in
elucidating the molecular pathology of hepatic tumors. In
the area of benign hepatocellular lesions, advances in our
understanding of molecular subtypes have led to a new
classiﬁcation system of HCA, with important genotype-
phenotype correlations and easy application to routine
clinical practice. In the ﬁeld of early hepatic neoplasia,
microarray studies of gene expression have identiﬁed sim-
ple molecular signatures that can distinguish dysplastic
nodules from early HCCs in a background of cirrhosis.
Although such expression signatures can be determined
by quantitative RT-PCR, the use of immunohistochemistry,
which allows the simultaneous assessment of histology and
protein expression, is preferred in needle biopsies. Molecular
measures of prognosis in patients with HCCs and CC are
emerging; in retrospective studies, a variety of molecular
techniques have successfully identiﬁed subgroups of HCCs
with distinct clinical associations, such as prognosis, risk of
recurrence after attempted curative treatment, and response
to adjuvant interferon therapy. Although these assays are
not yet developed for widespread clinical application, their
reﬁnement and use for the stratiﬁcation of patientsundergo-
ing treatment in clinical trials will lead to further advances
in therapeutic options for liver cancer. The current system
ofclassifying hepatic tumorsbased onhistologic architecture
and patterns of diﬀerentiation has many limitations. Molec-
ularstudieshavesupportedamodelofhepatictumorigenesis
in which neoplasms recapitulate various lineages and stages
of hepatic progenitor cell diﬀerentiation. These discoveries
are likely to have an important impact on liver tumor
classiﬁcation and to lead to a newer classiﬁcation system,
based on histologic and molecular features, with improved
prognostic and therapeutic signiﬁcance.
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